Description

Update in Urologic Oncology 2026 (Videos + PDFs) | GU Cancer Board Review

Update in Urologic Oncology 2026 – Comprehensive GU Cancer Care Course

Strengthen your clinical approach to genitourinary malignancies with the Update in Urologic Oncology 2026. This comprehensive, expert-led video course provides a practical review of the full spectrum of genitourinary oncology, including prostate cancer, bladder cancer, kidney cancer, testicular cancer, penile cancer, adrenal tumors, survivorship, robotic surgery, systemic therapy, advanced imaging, biomarkers, and multidisciplinary cancer care.

Designed for clinicians managing complex GU cancers, the program reviews recent clinical trials, evolving treatment standards, guideline-based decision-making, new diagnostic tools, surgical techniques, radiation therapy, immuno-oncology, genomic testing, and systemic treatment strategies.

With approximately 22.75 hours of educational content, this course is ideal for board preparation, clinical knowledge updates, and improving day-to-day decision-making in urologic oncology practice.

Course Details

• Original Release Date: May 31, 2026
• Estimated Duration: 22.75 Hours
• Format: On-Demand Video Course
• Included: Video Lectures + PDF Files
• Sample Video: Contact us for a sample video
• Access: Digital delivery for convenient study and offline viewing

Who Should Take This Course?

This educational program is designed for:

• Urologists
• Urologic Oncologists
• Medical Oncologists
• Radiation Oncologists
• Surgical Oncologists
• Urology Fellows and Residents
• Oncology Fellows
• Advanced Practice Providers involved in GU cancer care
• Clinicians preparing for urology or oncology board examinations

Course Overview

The Update in Urologic Oncology 2026 delivers clinically relevant education covering the diagnosis, staging, treatment, follow-up, and survivorship of patients with genitourinary cancers.

The course includes disease-specific treatment algorithms, current guideline updates, pivotal trial data, emerging systemic therapies, biomarker-driven care, genomic classifiers, advanced imaging, minimally invasive surgery, robotic procedures, radiation therapy, and multidisciplinary treatment planning.

Participants will gain practical tools to interpret new evidence and apply it to real-world clinical workflows across academic, hospital, and community-based oncology practices.

Key Areas Covered

Prostate Cancer

• Contemporary PSA-based screening
• Risk-adapted prostate cancer screening
• Prostate biopsy techniques and pitfalls
• Genomic classifiers for screening and risk stratification
• Active surveillance
• Robotic-assisted radical prostatectomy
• Focal therapy
• Radiation therapy for low-, intermediate-, and high-risk disease
• Oligometastatic prostate cancer
• Biochemical recurrence
• Advanced and metastatic prostate cancer
• Sexual health and treatment-related complications
• Erectile dysfunction and urinary incontinence
• Prostate cancer survivorship

Bladder and Urothelial Cancer

• Microscopic and gross hematuria evaluation
• Non-muscle-invasive bladder cancer
• Risk stratification and treatment
• Muscle-invasive bladder cancer
• Neoadjuvant chemotherapy
• Adjuvant systemic therapy
• Radical cystectomy
• Urinary diversion
• Trimodality bladder-preservation protocols
• Upper-tract urothelial carcinoma
• Sexual health after radical cystectomy

Kidney and Renal Cell Carcinoma

• Renal mass detection and staging
• Advanced imaging strategies
• Management of small renal masses
• Open and robotic surgical approaches
• Cytoreductive nephrectomy
• Venous tumor thrombi
• Radiation therapy in renal cell carcinoma
• Systemic therapy for advanced RCC
• Non-clear-cell renal cancers
• Hereditary RCC syndromes

Testicular and Germ-Cell Tumors

• Early-stage germ-cell tumors
• Metastatic germ-cell cancer
• Surgical and systemic treatment strategies
• Long-term management and survivorship

Penile Cancer

• Organ-confined penile cancer
• Locally advanced and metastatic disease
• Surgical and multidisciplinary treatment planning

Adrenal Tumors

• Diagnosis and management of benign adrenal lesions
• Evaluation of malignant adrenal masses
• Surgical considerations for urologists

Emerging and Multidisciplinary Topics

• Artificial intelligence in GU cancer care
• Clinical trial interpretation
• Epidemiology and global burden of GU malignancies
• Frailty assessment
• Enhanced recovery after surgery
• Palliative and end-of-life care
• Smoking cessation
• Pediatric urologic oncology
• Robotic surgery performance and efficiency
• Value-based and patient-centered cancer care

Learning Objectives

After completing this activity, learners should be able to:

• Interpret recent NCCN and AUA guideline updates and pivotal clinical trial data.
• Optimize the management of localized, recurrent, and advanced genitourinary cancers.
• Integrate imaging, genomic, molecular, and biomarker information into personalized treatment plans.
• Develop multidisciplinary strategies that appropriately sequence surgery, systemic therapy, radiation therapy, and survivorship care.
• Apply evidence-based approaches to improve care coordination and patient outcomes.
• Evaluate emerging therapies and evolving standards of care in GU oncology.
• Incorporate patient preferences, quality-of-life considerations, and survivorship goals into clinical decision-making.
• Translate new research findings into practical clinical workflows.

Complete Topics

1. Understanding the Global Epidemiology and Burden of Genitourinary Cancers
2. Clinical Trial Design and Interpretation for the Busy Surgeon
3. Contemporary PSA-Based Screening for Prostate Cancer
4. Prostate Biopsy: Techniques, Pitfalls, and Future Directions
5. Genomic Classifiers Part 1: Prostate Cancer Screening Risk Assessment
6. Genomic Classifiers Part 2: Prostate Cancer Risk Stratification
7. Active Surveillance in Prostate Cancer
8. Robotic-Assisted Radical Prostatectomy: Novel Techniques
9. Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer
10. Radiation Therapy for High-Risk and Locally Advanced Prostate Cancer
11. Focal Therapy for Prostate Cancer
12. Prostate Cancer Survivorship After Radical Prostatectomy
13. Oligometastatic and Biochemical Recurrence of Prostate Cancer
14. Advanced Prostate Cancer: Locally Advanced Systemic Therapy
15. Advanced Prostate Cancer: Metastatic Systemic Therapy
16. Treatment-Related Adverse Effects, Sexual Health, and Survivorship
17. Contemporary Evaluation of Microscopic and Gross Hematuria
18. Non-Muscle-Invasive Bladder Cancer: Diagnosis and Risk Stratification
19. Non-Muscle-Invasive Bladder Cancer: Treatment
20. Neoadjuvant Chemotherapy Before Radical Cystectomy
21. Adjuvant Therapy for Muscle-Invasive Bladder Cancer
22. Radical Cystectomy, Surgical Approaches, and Urinary Diversions
23. Trimodality Bladder-Preservation Protocols
24. Upper-Tract Urothelial Carcinoma
25. Novel Imaging Strategies in Renal Mass Detection and Staging
26. Management of Small Renal Masses
27. Open Surgical Approaches for Renal Masses
28. Robotic Approaches for Small Renal Masses
29. Advanced RCC, Venous Tumor Thrombi, and Cytoreductive Nephrectomy
30. Radiation Therapy for Renal Cell Carcinoma
31. Systemic Therapy for RCC
32. Non-Clear-Cell Renal Masses and Hereditary RCC Syndromes
33. Early-Stage Germ-Cell Tumors
34. Metastatic Germ-Cell Cancer
35. Organ-Confined Penile Cancer
36. Advanced Penile Cancer
37. Enhanced Recovery After Surgery
38. Palliative and End-of-Life Care
39. Artificial Intelligence Applications for GU Cancers
40. Sexual Health in Women Undergoing Radical Cystectomy
41. Pediatric Urologic Oncology
42. Frailty Assessments in GU Cancer Patients
43. Benign Adrenal Lesions
44. Malignant Adrenal Masses
45. Smoking Cessation in Genitourinary Cancer Care
46. Performance and Efficiency in Robotic-Assisted Procedures

Why Choose This Course?

• Comprehensive coverage of all major genitourinary cancers
• Approximately 22.75 hours of expert-led education
• Video lectures and PDF materials included
• Latest treatment approaches and clinical trial updates
• Board-relevant review of prostate, bladder, kidney, testicular, penile, and adrenal cancers
• Practical guidance for multidisciplinary cancer care
• Valuable for both board preparation and clinical practice